Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top

Current Oncology Reports

Issue 2/2009

Content (11 Articles)

Clinical Trials Report

Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer

Ronald M. Bukowski

Myeloid-derived suppressor cells: A novel therapeutic target

Jennifer S. Ko, Ronald M. Bukowski, James H. Fincke

VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy

C. Lance Cowey, W. Kimryn Rathmell

Perifosine: Update on a novel Akt inhibitor

Joell J. Gills, Phillip A. Dennis

Angiopoietin-2: Development of inhibitors for cancer therapy

Bo Hu, Shi-Yuan Cheng

Jak2 inhibitors: Rationale and role as therapeutic agents in hematologic malignancies

Jacqueline Sayyah, Peter P. Sayeski

The chemokine receptors CXCR4 and CXCR3 in cancer

Amy M. Fulton

Sarcomas of the head and neck region

Thomas D. Shellenberger, Erich M. Sturgis

Quality of life of oropharyngeal cancer patients treated with brachytherapy

David N. Teguh, Peter C. Levendag, Inger-Karine Kolkman-Deurloo, Peter van Rooij, Paul I. M. Schmitz

Surgical salvage of cancer of the oropharynx after chemoradiation

Jeffrey M. Bumpous

Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies

Steve C. Lee, Andrés López-Albaitero, Robert L. Ferris

Jan 09
Issue: 1/2009
May 09
Issue: 3/2009

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits